PLAY PODCASTS
Key HIV Studies Influencing My Practice Following IDWeek 2021 – Audio Recap
Episode 91

Key HIV Studies Influencing My Practice Following IDWeek 2021 – Audio Recap

Listen to expert insights from Darcy Wooten, MD, on updates and new HIV data from IDWeek 2021, including 2-drug ART, metabolic outcomes, investigational agents, and survey data of the U=U educational campaign.

Decera Clinical Education Infectious Disease Podcast · Darcy Wooten MD

October 11, 202141m 36s

Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

In this episode, Darcy Wooten, MD, discusses new HIV data from IDWeek 2021, including:

  • A rapid test-and-treat program to start DTG/3TC in patients newly diagnosed with HIV (STAT)
  • Efficacy when switching from 3-drug to 4-drug TAF-based regimens to DTG/3TC (TANGO)
  • Virologic outcomes with 2-drug vs 3-drug ART regimens (Trio Health HIV Network Study)
  • Metabolic complications in treatment-naive patients (Study 1489 and Study 1490)
  • Resistance analysis of an investigational agent, lenacapavir (CALIBRATE)
  • The Positive Perspectives Survey to evaluate the U=U Educational Campaign in North American patients

Presenter:

Darcy Wooten, MD
Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California

Link to full program:
https://bit.ly/3BCHF2E


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Topics

positive perspectives surveyundetectable equals untransmittablem184idolutegravirobesityabcm184resistance analysis3-drug regimenrenal outcomesbic2drmetabolic outcomesundetectabletrio health hiv networkvirologic suppressionuntransmittabledtgsexual healthviral suppressionmental healthabacavirviral loadweightoverweightbic/ftc/tafcalibratelamivudinetenofovir alafenamidestudy 14903tclenacapavirbictegravirpk3drinflammatoryu=u educational campaignlipidsweight gain2-drug regimensrenaltreatment-emergent resistanceoptimal sexual healthdtg/abc/3tcmetabolicoptimal mental healthinflammatory biomarkerspharmacokineticsresistanceidweekm184vstudy 1489nrtivirologic failureinflammatory markersstatlenm184i/vf/tafdtg/3tctafcapsidtangoarthivu=u